What price restored eyesight? US firm says $850,000…
Monday 29 January 2018One of the most expensive drugs ever sold has just been approved for sale in the US by the Federal Drug Administration (FDA). But this is no ordinary drug. Spark Therapeutics, who produce Luxturna, claim it can cure a rare form of blindness.
For $425,000 per eye, sufferers of blindness due to retinal dystrophy can purchase a one-off injection of the drug which was shown to restore sight in clinical trials. In fact the trial was so successful that the drug has become the first gene therapy of its type to be approved by the FDA. However, the injections carry no guarantee. Consequently, Spark are offering a range of discounts should the drug fail initially or over time.
There is potential good news for those living in the UK, as Luxturna has been submitted for approval by the European Medicines Agency (EMA). EMA approval would mean that the drug can be considered by the National Institute for Health Care Excellence (NICE) - the first step towards possible free availability on the NHS.
Sources:
Comments
Post a comment…
A Serious Blog
News and views from around the world on lighting, eyecare and eye conditions.
Twitter: @seriousreaders
Facebook:facebook.com/seriousreaders
Recent posts
- Spring forward: Your guide to the 2024 British Summer Time shift
- A spark of genius - the history of the light bulb
- A worded world: Celebrating the Oxford English Dictionary's legacy
- High street cataract and glaucoma tests to reduce NHS waiting lists?
- Eye health resolutions for 2024: your comprehensive guide to preserving and enhancing eyesight
Browse by label
- AMD
- AMD Sight News
- Blue Light
- Cataracts
- Diabetic Retinopathy
- Glaucoma
- Glaucoma Sight News
- Light News
- Light News Glaucoma Sight News
- Light News Sight News
- Literary Festivals
- Literary Festivals Literary News
- Literary News
- OCT Scans: A New Tool In Multiple Sclerosis Diagnosis
- Serious News
- Sight News
- Sight News AMD
- Sight News Blue Light
- Sight News Cataracts
- Sight News Glaucoma
Subscribe to our email newsletter and claim your FREE copy of our popular guide '9 Top Tips to Save Your Sight'